Mesoblast Ltd. (NASDAQ: MESO) is a clinical-stage biotechnology company specializing in regenerative medicine, with a focus on allogeneic cellular therapies derived from mesenchymal lineage cells. Founded in 2004 by Dr. Silviu Itescu, Mesoblast has pioneered proprietary manufacturing processes and scalable production platforms to develop off-the-shelf cell therapies aimed at treating severe inflammatory and life-threatening conditions. The company’s scientific approach leverages the immunomodulatory and reparative properties of mesenchymal stem cells (MSCs) to address unmet medical needs in a variety of serious diseases.
Mesoblast’s lead commercial product, TEMCELL® HS (remestemcel-L), is approved in Japan for steroid-refractory acute graft-versus-host disease (aGVHD) in pediatric patients, marking one of the first globally recognized MSC therapies to achieve regulatory approval. In addition to its commercial presence in Asia, Mesoblast has a robust late-stage pipeline in the United States, Europe and other markets, including Phase 3 trials for pediatric steroid-refractory aGVHD, chronic heart failure, inflammatory bowel diseases and degenerative disc disease. The company collaborates with strategic partners and academic institutions to advance its clinical programs and to explore potential new indications for its cell-based platform.
Headquartered in New York, with research operations in Melbourne and manufacturing sites in the United States, Mesoblast operates across North America, Europe and Asia-Pacific regions. The company’s integrated global footprint supports streamlined clinical development, regulatory submissions and commercial launch capabilities for current and future therapies. This geographic reach enables Mesoblast to engage with diverse patient populations, regulatory bodies and healthcare systems to accelerate the adoption of its allogeneic cell medicines on a worldwide scale.
Under the leadership of Dr. Silviu Itescu as Chief Executive Officer and a board of directors with deep expertise in biotechnology, regenerative medicine and commercial strategy, Mesoblast continues to advance its vision of transforming patient care through novel cell-based therapies. The management team’s combined experience in clinical development, regulatory affairs and global commercialization underpins the company’s ongoing efforts to deliver innovative treatments for debilitating diseases that currently have limited therapeutic options.
AI Generated. May Contain Errors.
Free MESO Stock Alerts